

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, RMTI, ORCL, AMPE and CBS
Tuesday, September 04, 2018 09:08:57 PM (GMT)

NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)

Class Period: April 29, 2016 to July 9, 2018

Lead Plaintiff Deadline: September 17, 2018

According to the complaint, ACADIA Pharmaceuticals Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) adverse events and safety concerns related to NUPLAZID threatened the drug's initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result, defendants' statements about ACADIA's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Get additional information about the **ACAD** lawsuit: <http://www.kleinstocklaw.com/pslra-c/acadia-pharmaceuticals-inc?wire=3>

Rockwell Medical, Inc. (NASDAQ: RMTI)

Class Period: March 16, 2018 to June 26, 2018

Lead Plaintiff Deadline: September 25, 2018

Rockwell Medical, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that The Centers for Medicare and Medicaid Services will not pursue Rockwell's proposal for separate reimbursement for the drug Triferic; (2) the estimated reserves in the first quarter 2018 10-Q are misstated; (3) there was a material weakness in Rockwell's internal controls over financial reporting; (4) consequently, Rockwell's internal controls over financial reporting were ineffective during the Class Period; (5) Defendant Chioini withheld material information regarding Triferic from Rockwell's auditor, corporate counsel and five independent directors of the Board; and (6) as a result, Defendants' statements about the Company's business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.

Get additional information about the **RMTI** lawsuit: <http://www.kleinstocklaw.com/pslra-c/rockwell-medical-inc?wire=3>

Oracle Corporation (NYSE: ORCL)

Class Period: May 10, 2017 to March 19, 2018

Lead Plaintiff Deadline: October 9, 2018

The complaint alleges that throughout the Class Period defendants issued false and misleading statements regarding Oracle's cloud revenues and failed to disclose that these revenues were driven, at least in part, by improper, coercive sales practices, including: (1) threatening existing customers with "audits" of their use of Oracle's non-cloud software licenses and levying expensive penalties against those customers, unless the customers agreed to shift their business to Oracle cloud programs; (2) decreasing customer support for certain Oracle on-premises or hardware systems, in an effort to drive customers away from such systems and into cloud-based systems; and (3) strong-arming customers by threatening to raise the cost of legacy database licenses dramatically if the customers choose another cloud provider.

Get additional information about the **ORCL** lawsuit: <http://www.kleinstocklaw.com/pslra-c/oracle-corporation?wire=3>

Ampio Pharmaceuticals, Inc. (NYSEAmerican: AMPE)

Class Period: December 14, 2017 to August 7, 2018

Lead Plaintiff Deadline: October 24, 2018

The complaint alleges that throughout the class period Ampio Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the FDA would find Ampio's AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; (3) consequently, Defendants' public statements were materially false and misleading at all relevant times.

Get additional information about the **AMPE** lawsuit: <http://www.kleinstocklaw.com/pslra-1/ampio-pharmaceuticals-inc-loss-form?wire=3>

CBS Corporation (NYSE: CBS)

Class Period: February 14, 2014 to July 27, 2018

Lead Plaintiff Deadline: October 26, 2018

The lawsuit alleges CBS Corporation made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) CBS executives, including the company's Chairman and Chief Executive Officer, Leslie "Les" Moonves, had engaged in widespread workplace sexual harassment at CBS; (2) CBS's enforcement of its own purported policies was inadequate to prevent the foregoing conduct; (3) the foregoing conduct, when revealed, would foreseeably subject CBS to heightened legal liability and impede the ability of key CBS personnel to execute the company's business strategy; and (4) as a result, CBS's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Get additional information about the **CBS** lawsuit: <http://www.kleinstocklaw.com/pslra-1/cbs-corporation-loss-form?wire=3>

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com



Primary Identifiers: ACAD-US, AMPE-US, CBS-US, ORCL-US, RMTI-US

Related Identifiers: ACAD-US, AMPE-US, CBS-US, ORCL-US, RMTI-US, ACAD, AMPE, VIAC, 92556H20, ORCL, RMTI

Subjects: Class Action, Law & Legal Issues